REPO4EU

Join us for a crucial conversation as we aim to establish a new Special Interest Group for the reimbursement of repurposed drugs in Europe 💊 🇪🇺 On 15th January 2025, we'll be hosting the first hybrid policy kick-off event in Brussels, where the REPO4EU consortium -with the support of the EU- will be putting forward the proposal of creating a Special Interest Group (SIG), with the goal of advocating for a coordinated European reimbursement guideline for repurposed drugs. We invite clinicians, researchers, policy-makers, corporate representatives to take part in this event to help us advance drug repurposing across the EU and discuss potential contributions towards drafting a set of reimbursement guidelines that can ensure rapid and cost-effective patient benefit from these advancements. Find out more on our website and register to attend in-person or online 👉 https://lnkd.in/eFx-XYCA #EUfunded by European Health and Digital Executive Agency (HaDEA) #DrugRepurposing #FutureOfMedicine #PharmaInnovation

Reimbursement policies are at the heart of making repurposed drugs available, but some hurdles around reimbursement still persist across Europe, delaying patient access to these innovative treatments. What processes can we set up to overcome current obstacles? Meet the panellists who will be sharing their views on this and other key topics at our upcoming hybrid event, focused on exploring innovative and sustainable models for drug repurposing in Europe 👉 https://lnkd.in/eFx-XYCA Session 4: Innovating Reimbursement of Repurposed Drugs for Fair Returns on Investments 🟣 François Houÿez - EURORDIS-Rare Diseases Europe 🟣 Sabine Grimm - Maastricht UMC+ 🟣 Sibylle R. - AIM - Association Internationale de la Mutualité/International Association of Mutuals 🟣 Sibren van den Berg - Medicijn voor de Maatschappij #EUfunded by European Health and Digital Executive Agency (HaDEA) #DrugRepurposing #FutureOfMedicine #HealthcareInnovation

Innovation in medicine is more than discovery — it’s about delivering cures to the patient. But how can we find the balance between providing fair return on investments for companies backing repurposed drugs while ensuring patients can afford these treatments? Meet the panellists who will be sharing their views on this and other key topics at our upcoming hybrid event, focused on exploring innovative and sustainable models for drug repurposing in Europe 👉 https://lnkd.in/eFx-XYCA Session 3: Successes and Roadblocks in Bringing Drug Repurposing to the Patient 🟣 Barend Bouma - NLO | European patent and trademark attorneys 🟣 Saco de Visser - Future Affordable Sustainable Therapies 🟣 Hugo Filipe - Politécnico da Guarda / RePo-SUDOE 🟣 Teun Grooters - Arega Medical 🟣 Hermann Mucke - H.M. Pharma Consultancy Check the full agenda, and sign up to attend in-person or online on 15 January ➡️ https://lnkd.in/eFx-XYCA 🇪🇺 #EUfunded by European Health and Digital Executive Agency (HaDEA) #DrugRepurposing #FutureOfMedicine #HealthcareInnovation

Join us if you are burning for the topic of repurposing drugs.

Thanks to innovative testing and regulatory approaches, repurposed drugs can demonstrate treatment efficacy faster than ever. But, in an evolving landscape, how can regulators and researchers collaborate to reshape the future of medicine? Meet the panellists who will be sharing their views on this and other key topics at our upcoming hybrid event, focused on exploring innovative and sustainable models for drug repurposing in Europe 👉 https://lnkd.in/eFx-XYCA Session 2: Regulatory Innovations Facilitating Drug Repurposing 🟣 Matthew Fedowitz - Buchanan Ingersoll & Rooney PC 🟣 Aaron S. Kesselheim, M.D., J.D., M.P.H. - Harvard Medical School 🟣 Yoana Nuevo-Ordóñez, PhD - Agencia Española de Medicamentos y Productos Sanitarios 🟣 Marjon Pasmooij - Medicines Evaluation Board (CBG-MEB) 🟣 Anja Schiel - Norwegian Medical Products Agency Check the full agenda, and sign up to attend in-person or online on 15 January ➡️ https://lnkd.in/eFx-XYCA 🇪🇺 #EUfunded by European Health and Digital Executive Agency (HaDEA) #DrugRepurposing #FutureOfMedicine #HealthcareInnovation

When it comes to drug repurposing, taking a patient-centered approach is key to achieve safe, efficient and precise cures. But how can we work more efficiently with patient organisations to make this a reality? Meet the panellists who will be sharing their views on this and other key topics at our upcoming hybrid event, focused on exploring innovative and sustainable models for drug repurposing in Europe 👉 https://lnkd.in/eFx-XYCA Session 1: The patients’ and patient organisations’ view 🟣 Marcos Mengual Hinojosa - SYNGAP Elternhilfe e.V. 🟣 Anneliene Jonker - Duchenne Parent Project 🟣 Ellen Koekoeckx - Foundation for Angelman Syndrome Therapeutics 🟣 Joachim Maurice Mielert - Aktionsbündnis Patientensicherheit e. V. 🟣 Bernd Rosenbichler - Branewo Check the full agenda, and sign up to attend in-person or online on 15 January ➡️ https://lnkd.in/eFx-XYCA 🇪🇺 #EUfunded by European Health and Digital Executive Agency (HaDEA) #DrugRepurposing #FutureOfMedicine #HealthcareInnovation

Who shouldn't miss our upcoming event focused on sustainable models for #DrugRepurposing in the EU? 💊 Prof. Harald H.H.W. Schmidt, REPO4EU Project Coordinator, responds: "We want to gather all the relevant voices into one room to share ideas, exchange knowledge and discuss how we can overcome existing roadblocks. So I'm hoping to see scientists, clinicians, regulators, patient group representatives and health technology assessors coming along to this big brainstorming session." 📢 Don't miss out on this opportunity to share your thoughts on how we should be working together to build innovative, efficient and sustainable models for repurposed drugs, so we can bring these treatments to patients faster and for a fair price. Check the full agenda for this hybrid event and register to attend, for free, on 15 January (in Brussels or online) 👉 https://lnkd.in/eFx-XYCA 🇪🇺 #EUfunded by European Health and Digital Executive Agency (HaDEA) #FutureOfMedicine #HealthcareInnovation #DrugDiscovery #DrugResearch #MedicalCommunity #HTA David Cavalla Marcos Mengual Hinojosa Anneliene Jonker Joachim Maurice Mielert Ellen Koekoeckx Bernd Rosenbichler Matthew Fedowitz Aaron S. Kesselheim, M.D., J.D., M.P.H. Yoana Nuevo-Ordóñez, PhD Marjon Pasmooij Anja Schiel Barend Bouma Saco de Visser Hugo Filipe Teun Grooters Hermann Mucke François Houÿez Manuela Joore Sibylle R. Sibren van den Berg

DRUG REPURPOSING FOR PARKINSON‘S DISEASE REPO4EU

🎉 We're thrilled to announce the publication of our research work on the proof of concept of “Clinicalyzer”, a state of the art module within the NEXUS-Rx framework. This case study delves into the complexities of Prader-Willi Syndrome (PWS), shedding light on critical gaps and unmet clinical needs in genetic obesity. 🦚 We're incredibly proud of the entire team: Manish Sarkar, Henning von Horsten, Dimitrije M., Nathalie Barreto Lefebvre and Soham Saha, Ph.D., who contributed to this article on “Clinicalyzer” in Prader-Willi Syndrome. This study is a part of the MBA&E thesis work performed by Manish Sarkar at MBA & Engineering in Life Science Management Programme, HTW Berlin, Germany. Warm thanks to Jette Wienprecht and Katja Krebs-Ali for your support. 🔗 Here is the publication link: https://lnkd.in/g2yP4gpE 💡 The dedication, expertise, and innovative thinking from the entire team have provided us with the opportunity to understand rare disease space. ⚡ Key Highlights: #ClinicalEfficacyLandscaping: Unraveling the intricate landscape of PWS treatment options. #Marketanalysis: Identifying key market players in the space to educate and inform optimal business decision making. #UnmetNeeds: Highlighting the unmet need for therapeutic solutions in genetic obesity. 🤖 Clinicalyzer is poised to provide a comprehensive understanding of disease mechanisms, clinical trial landscape and treatment responses. 🙏 We are grateful to Harald H.H.W. Schmidt 🕸️💊 and Stephanie Dawson for providing us the opportunity within #REPO4EU initiative to present a part of this work at #REXPO24 in Munich, and for valuable feedbacks. 🙏 We are also grateful to Serge Luquet, Oliver Weyand, Paolo Parini and Robert P. Loewe for their valuable suggestions and guidance. 🌟 We are looking forward to 2025 with new exciting developments. #PraderWilliSyndrome #GeneticObesity #Clinicalyzer #NEXUSRx #Healthcare #Biotechnology #MedInsights #HTWBerlin #REPO4EU

We are wrapping up 2024 with three major announcements for 2025 👇 🇪🇺 Our first hybrid policy event in Brussels, which marks the next step in our advocacy work for sustainable drug repurposing models 📃 The second edition of our Drug Repurposing Journal, launched in collaboration with our colleagues from ScienceOpen 💊 And the unveiling of the dates and location for #RExPO25, the 4th edition of our annual conference on Systems Medicine, AI & Drug Repurposing Check out our latest newsletter to find all the details, and don't forget to subscribe 😎 In the words of our Project Coordinator, Harald H.H.W. Schmidt — Stay engaged, stay disruptive! #DrugRepurposing #FutureOfMedicine #HealthcareInnovation #EUfunded